Ultimovacs – executive interview

Ultimovacs – executive interview

Ultimovacs — 7 videos in collection

Ultimovacs is developing novel immunotherapies against cancer. The lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (human telomerase reverse transcriptase), which is expressed in c 85% of all cancer types. UV1 therefore has broad potential in a variety of different settings and combinations.

In this video, CMO Jens Bjørheim shares encouraging three-year survival data for UV1.


You may also be interested in these:

Healthcare

Ultimovacs – executive interview

Ultimovacs

Healthcare

Ultimovacs - executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.